Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...
Before CagriSema, Novo Nordisk already had Wegovy, which has been quite successful as a weight loss drug. Zepbound (tirzepatide ... Nordisk's performance with charts, breakdowns, 30-year financial ...
Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback